The Claim
Administration of ACE-031 to common marmosets over 14 weeks is not associated with adverse changes in serum chemistries or gross tissue morphology, despite the occurrence of vascular adverse events in prior human trials, indicating species-specific differences in tolerability.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In common marmosets given ACE-031 for 14 weeks, no harmful changes were observed in blood chemistry or tissue structure, even though similar treatment in humans caused blood vessel problems, suggesting the two species respond differently to this compound.
See the scientific wording
The safety profile of ACE-031 in common marmosets over 14 weeks shows no adverse effects on serum chemistries or gross tissue morphology, despite prior human trials reporting vascular adverse events, suggesting species-specific differences in tolerability.
ACE-031 binds to proteins that normally limit muscle growth, stopping them from sending signals that break down muscle tissue; this makes muscles bigger and stronger, and in marmosets, this process does not harm blood vessels or organs, unlike in humans where the same drug causes bleeding and vascular problems.
What the research says
1 studyIn monkeys, ACE-031 made muscles bigger and stronger without causing any visible harm, even though it caused bleeding in people — suggesting monkeys and humans react differently to the drug.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.